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Background
HIV-1 has been classified into 4 groups: M, N, O and P.
The aim was to revisit the cross-group neutralization
using a highly diverse panel of primary isolates (PI) and
human monoclonal neutralizing antibodies (mAb).
Methods
The panel of viruses included 9 HIV-1 group O PIs, 1
recombinant M/O PI, 1 group N PI, 1 group P PI, 2
group M (subtype B) PIs and the HIV-1 group M
adapted strain MN. All the viruses were tested for neu-
tralization in TZM-bl cells, using a panel of sera issued
from patients infected by HIV-1 group M viruses
(n=11), HIV-1 groups O (n=12) and P (n=1). The mAbs
were b12, 2G12, 2F5, 4E10, PG9, PG16, VRC01, VRC03
and HJ16.
Results
The 12 group O sera neutralized from 1 to 6 group O
viruses, and 6 of them cross-neutralized one group M PI.
Five of the 10 group M sera cross-neutralized from 4 to 9
group O PIs. The group N and P viruses were neutralized
by 1-4 of 12 and 4-5 of 11 sera from groups O and M
patients, respectively. The human mAbs did not show any
cross-group neutralization, except PG9 and PG16. Two
group O PIs were neutralized by both PG9 and PG16, and
one group O PI was neutralized by PG9 only. The group
N PI was highly sensitive to neutralization by PG9 and
PG16. The N-linked glycans at positions 156 and 160 and
the cationic residues of strand C of the V1/V2 domain
that have been identified as part of the PG9 epitope are
conserved among the group N.
Conclusion
The cross-group neutralization of HIV-1 has been
demonstrated. The conservation of the PG9 and PG16
epitopes between groups provides an argument for their
relevance as components of a potentially efficient HIV
vaccine.
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